Table 3 Impact of CAV1 genotype on graft histological lesions

Systematic

n = 10

n = 43

n = 69

 Acute tubular necrosis

0

0

1 (1.4%)

 Tacrolimus acute tubular toxicity

1 (10.0%)

7 (16.3%)

18 (26.1%)

 Tacrolimus chronic vascular toxicity

1 (10.0%)

5 (11.6%)

7 (10.1%)

 Acute rejection (cellular or humoral)

0

1 (2.3%)

7 (10.1%)

 IF/TA grade I or II

5 (50.0%)

14 (32.6%)

18 (26.1%)

 IF/TA grade III

0

1 (2.3%)

1 (1.4%)

Clinically indicated biopsies

n = 7

n = 38

n = 49

 Acute tubular necrosis

2 (28.6%)

12 (31.6%)

11 (22.4%)

 Tacrolimus acute tubular toxicity

1 (14.3%)

5 (13.2%)

9 (18.4%)

 Tacrolimus chronic vascular toxicity

2 (28.6%)

7 (18.4%)

9 (18.4%)

 Acute rejection (cellular or humoral)

1 (14.3%)

9 (23.7%)

11 (22.4%)

 IF/TA grade I or II

5 (71.4%)^*

11 (28.9%)^*

5 (10.2%)^*

 IF/TA grade III

0

1 (2.6%)

3 (6.1%)

Total of biopsies

n = 17

n = 81

n = 118

 Acute tubular necrosis

2 (11.8%)

12 (14.8%)

12 (10.2%)

 Tacrolimus acute tubular toxicity

3 (17.6%)

12 (14.8%)

27 (22.9%)

 Tacrolimus chronic vascular toxicity

3 (17.6%)

12 (14.8%)

16 (13.5%)

 Acute rejection (cellular or humoral)

1 (5.9%)

10 (12.3%)

11 (9.3%)

 IF/TA grade I or II

10 (58.8%)^**

25 (30.8%)^**

23 (19.5%)^**

 IF/TA grade III

0

3 (3.7%)

3 (2.5%)

 BK virus nephropathy

2 (11.8%)

3 (3.7%)

4 (3.4%)